NCT04983199 Patient Reported Outcomes/Metrics Program Trial
| NCT ID | NCT04983199 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Metastatic Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-11-24 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2022-11-24 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational study to investigate if it is feasible to recruit 100 patients receiving radiotherapy (RT) to metastatic disease to wear Hexoskin and if Hexoskin will facilitate the monitoring, detection and early treatment of RT-related side effects.
Eligibility Criteria
Inclusion Criteria: * Planned to receive palliative radiotherapy for pain * Known cancer diagnosis * Able to wear Hexoskin Medical Shirt * Ability to use and populate the mobile app (Zamplo) with or without assistance * ECOG: 0-3 * Willing to provide a list of analgesic (pain relief) medication * Willing to complete questionnaires * Life expectancy of at least 3 months Exclusion Criteria: * Receiving whole brain radiotherapy * Major cognitive or psychiatric impairments * Pregnant women * Allergies to: polyester, synthetic fibers * Patients with pacemakers or implantable cardioverter-defibrillator (ICD) * Patients on a Holter Monitor
Contact & Investigator
Philip Wong
PRINCIPAL INVESTIGATOR
The Princess Margaret Cancer Foundation
Frequently Asked Questions
Who can join the NCT04983199 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04983199 currently recruiting?
Yes, NCT04983199 is actively recruiting participants. Contact the research team at philip.wong@rmp.uhn.ca for enrollment information.
Where is the NCT04983199 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT04983199 clinical trial?
NCT04983199 is sponsored by University Health Network, Toronto. The principal investigator is Philip Wong at The Princess Margaret Cancer Foundation. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.